Fusogenic vesicular stomatitis virus for the treatment of head and neck squamous carcinomas

Recombinant VSV-F confers a modest survival benefit for HNSCC in this orthotopic murine model. This oncolytic virus holds promise as a novel cancer treatment for recurrent HNSCC.